You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils
À propos des lignes directrices

Optimal Therapy for Patients Diagnosed with Multiple Myeloma and the Role of High-Dose Chemotherapy and Stem Cell Support

Version: 2 ID: 6-6 Version 2 jan 2012
Type of Content: Guidelines & Advice, Clinical
Document Status: Education and Information
Authors:
K. Imrie, J. Makarski, R. Esmail, R. Meyer, Hematology Disease Site Group

Patient Population

Adult patients with advanced-stage multiple myeloma and good performance status.

Research Question(s)

  1. What is the optimal chemotherapy for patients with multiple myeloma?
  2. In terms of survival, is peripheral blood stem cell or autologous bone marrow transplantation better than conventional chemotherapy?
  3. What is the relative efficacy of autologous and allogeneic transplantation?
  4. What specifics of the transplant manoeuvre can be recommended?
  5. When should transplantation be performed?
  6. Who should (should not) be transplanted?
pdf download Full Report (PDF) (1.39 Mo)